This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Diergaarde, B. Articles by White, E. Search for Related Content PubMed PubMed Citation Articles by Diergaarde, B. Articles by White, E.

Polymorphisms in Genes Involved in Sex Hormone Metabolism, Estrogen Plus Progestin Hormone Therapy Use, and Risk of Postmenopausal Breast Cancer

¹ Cancer Prevention Program, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center and ² Department of Epidemiology, University of Washington, Seattle, Washington; and ³ InterGenetics Incorporated, Oklahoma City, Oklahoma

Requests for reprints: Brenda Diergaarde, University of Pittsburgh Cancer Institute Research Pavilion-Suite 1.16, 5117 Centre Avenue, Pittsburgh, PA 15213. Phone: 412-623-5891; Fax: 412-623-3355. E-mail: bbd3{at}pitt.edu

Hormone therapy, estrogen plus progestin (E+P) particularly, is associated with increased risk of breast cancer. Functionally relevant polymorphisms in genes involved in sex hormone metabolism may alter exposure to exogenous sex hormones and affect risk of postmenopausal breast cancer. We evaluated associations of common polymorphisms in genes involved in estrogen and/or progesterone metabolism, E+P use, and their interactions with breast cancer risk in a case-control study of postmenopausal women (324 cases; 651 controls) nested within the VITAL cohort. None of the polymorphisms studied was, by itself, statistically significantly associated with breast cancer risk. E+P use was significantly associated with increased breast cancer risk (10 years versus never; odds ratio, 1.9; 95% confidence interval, 1.3-2.8; P_trend = 0.0002). Statistically significant interactions between CYP1A1 Ile⁴⁶²Val (P_interaction = 0.04), CYP1A1 MspI (P_interaction = 0.003), CYP1B1 Val⁴³²Leu (P_interaction = 0.007), CYP1B1 Asn⁴⁵³Ser (P_interaction = 0.04) and PGR Val⁶⁶⁰Leu (P_interaction = 0.01), and E+P use were observed. The increased risk of breast cancer associated with E+P use was greater among women with at least one rare allele of the CYP1A1 Ile⁴⁶²Val, CYP1A1 MspI, CYP1B1 Asn⁴⁵³Ser, and PGR Val⁶⁶⁰Leu polymorphisms than among women homozygous for the common allele of these polymorphisms. Risk of breast cancer increased little with increasing years of E+P use among women with at least one CYP1B1 Val⁴³² allele; a large increase in risk was seen among women homozygous for CYP1B1 Leu⁴³². Our results support the hypothesis that specific polymorphisms in genes involved in sex hormone metabolism may modify the effect of E+P use on breast cancer risk. (Cancer Epidemiol Biomarkers Prev 2008;17(7):1751–9)